Beigene (NASDAQ:BGNE) received a $120.00 price objective from analysts at Maxim Group in a report issued on Monday, December 18th. The brokerage presently has a “buy” rating on the stock. Maxim Group’s price objective indicates a potential upside of 16.19% from the company’s current price.
Other analysts also recently issued research reports about the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $95.00 price objective (up previously from $87.00) on shares of Beigene in a research report on Friday, October 6th. Robert W. Baird reaffirmed a “neutral” rating and issued a $83.00 price objective (up previously from $58.00) on shares of Beigene in a research report on Tuesday, November 14th. Zacks Investment Research raised shares of Beigene from a “hold” rating to a “buy” rating and set a $115.00 price objective for the company in a research report on Tuesday, October 3rd. Finally, Cowen reissued a “buy” rating on shares of Beigene in a research report on Monday, December 11th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. Beigene has an average rating of “Hold” and an average price target of $96.67.
Shares of Beigene (NASDAQ BGNE) traded up $1.44 during mid-day trading on Monday, hitting $103.28. 140,662 shares of the stock traded hands, compared to its average volume of 319,702. Beigene has a 1-year low of $31.70 and a 1-year high of $118.95. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.27 and a current ratio of 9.33. The stock has a market cap of $4,700.00 and a price-to-earnings ratio of -78.84.
Beigene (NASDAQ:BGNE) last posted its quarterly earnings results on Monday, November 13th. The company reported $2.54 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $2.31. The business had revenue of $220.21 million during the quarter, compared to analysts’ expectations of $1.55 million. During the same quarter in the previous year, the business posted ($1.08) EPS. equities analysts expect that Beigene will post -2.04 earnings per share for the current year.
In other Beigene news, CMO Jane Huang sold 1,000 shares of the firm’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $98.00, for a total value of $98,000.00. Following the sale, the chief marketing officer now directly owns 1,000 shares in the company, valued at $98,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CMO Amy C. Peterson sold 3,601 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $82.96, for a total value of $298,738.96. Following the completion of the sale, the chief marketing officer now owns 1,201 shares in the company, valued at $99,634.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 483,482 shares of company stock valued at $42,139,474. 19.90% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of BGNE. Renaissance Technologies LLC bought a new stake in shares of Beigene during the first quarter valued at about $238,000. Bank of America Corp DE raised its stake in shares of Beigene by 5.8% during the first quarter. Bank of America Corp DE now owns 20,199 shares of the company’s stock valued at $740,000 after purchasing an additional 1,116 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Beigene by 315.2% during the second quarter. Bank of Montreal Can now owns 18,610 shares of the company’s stock valued at $837,000 after purchasing an additional 14,128 shares in the last quarter. First Trust Advisors LP raised its stake in shares of Beigene by 2.2% during the second quarter. First Trust Advisors LP now owns 48,860 shares of the company’s stock valued at $2,199,000 after purchasing an additional 1,029 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Beigene during the second quarter valued at about $111,000. Institutional investors and hedge funds own 55.32% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Maxim Group Analysts Give Beigene (BGNE) a $120.00 Price Target” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/14/maxim-group-analysts-give-beigene-bgne-a-120-00-price-target.html.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.